Mangalam Drugs and Organics' Q1 FY 2025-26 Quarterly Results

Result Summary

• Mangalam Drugs and Organics Ltd reported a 43.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 25.1%.
• Its expenses for the quarter were down by 28.5% QoQ and 7.4% YoY.
• The net profit decreased 490.9% QoQ and decreased 614.9% YoY.
• The earnings per share (EPS) of Mangalam Drugs and Organics Ltd declined at 8.7 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Mangalam Drugs and Organics Ltd is a company operating within the pharmaceutical and chemicals industry, with a focus on the production of drugs and organic chemicals. The company is involved in the manufacturing of various pharmaceutical formulations and active pharmaceutical ingredients (APIs), which are crucial in the creation of medications. As of the latest available information, Mangalam Drugs and Organics Ltd has continued to be a significant player in its industry, although details on recent major developments are not provided in the available dataset.

Revenue

During Q1FY26, Mangalam Drugs and Organics Ltd reported a total income of ₹57.35 crores, a decrease of 43.9% compared to Q4FY25, where the total income was ₹102.28 crores. When compared year-over-year, the total income for Q1FY26 shows a decline of 25.1% from Q1FY25, which recorded ₹76.56 crores. This reflects the company's revenue performance over the specified periods, highlighting a substantial reduction in income both quarterly and annually.

Profitability

The company's profitability metrics for Q1FY26 indicate a negative trend. Profit Before Tax stood at a loss of ₹13.00 crores, contrasting sharply with a profit of ₹3.93 crores in Q4FY25 and ₹0.58 crores in Q1FY25. This represents a significant decline of 430.8% quarter-over-quarter and 2341.4% year-over-year. The Tax expense for Q1FY26 was ₹0.80 crores, an increase from ₹0.40 crores in the previous quarter and a reversal from a tax credit of ₹-2.10 crores in the same quarter last year. Profit After Tax also saw a substantial drop to a loss of ₹13.80 crores from a profit of ₹3.53 crores in Q4FY25 and ₹2.68 crores in Q1FY25, marking declines of 490.9% QoQ and 614.9% YoY, respectively.

Operating Metrics

The Earnings Per Share (EPS) for Q1FY26 was recorded at a negative ₹8.70, a significant decrease from ₹2.20 in Q4FY25 and ₹1.70 in Q1FY25. This marks a sharp decline of 495.5% quarter-over-quarter and 611.8% year-over-year. The EPS figures provide insight into the company's earnings performance per share, reflecting the steep decline in earnings as observed in other profitability metrics. The data available does not provide specifics on other operating metrics such as the company's debt-to-equity ratio, current ratio, or P/E ratio, which could further inform the financial analysis.